ArticleInternational journal of molecular medicine2020
Inhibition of miR‑155‑5p attenuates the valvular damage induced by rheumatic heart disease.
Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 54 citations in OpenAlex.
- Review
- Epigenetic advances in rheumatic heart disease.Journal of translational autoimmunity · 2025Review
- Chronic Mitral Valve Fibrosis in Rheumatic Heart Disease: From Immune Trigger to Inflammatory and Mechanical Progression.Journal of the American Heart Association · 2025Review
- Extracellular Vesicles in Calcific Aortic Valve Disease: From Biomarkers to Drug Delivery Applications.Biomolecules · 2025Review
- Association Between the Expression of T Helper Type 17 Cell-Related Cytokines and Valve Damage in Rheumatic Heart Disease.Molecular biotechnology · 2025Article
- Clinical significance and regulatory mechanism of miR-134-5p in rheumatic heart disease.BMC cardiovascular disorders · 2025Article
- Curcumin as a promising therapeutic agent for diabetic neuropathy: from molecular mechanisms to functional recovery.Diabetology & metabolic syndrome · 2025Review
- Exosomal non-coding RNAs: key regulators of inflammation-related cardiovascular disorders.European journal of medical research · 2025Review
- Anti-IL-17 Inhibits PINK1/Parkin Autophagy and M1 Macrophage Polarization in Rheumatic Heart Disease.Inflammation · 2025Article
- Article
- Exosomes and miRNAs in Cardiovascular Diseases and Transcatheter Pulmonary Valve Replacement: Advancements, Gaps and Perspectives.International journal of molecular sciences · 2024Review
- Article
- Methods for Establishing a Rat Model of Rheumatic Heart Disease.Reviews in cardiovascular medicine · 2024Review
- Emerging role of sphingolipids and extracellular vesicles in development and therapeutics of cardiovascular diseases.International journal of cardiology. Heart & vasculature · 2024Review
- Detection and management of latent rheumatic heart disease: a narrative review.Annals of medicine and surgery (2012) · 2023Review
- Alpha-1-antitrypsin in serum exosomes and pericardial fluid exosomes is associated with severity of rheumatic heart disease.Molecular and cellular biochemistry · 2023Article
- Non-coding RNA mediates endoplasmic reticulum stress-induced apoptosis in heart disease.Heliyon · 2023Review
- Article
- Challenges and promise of targeting miRNA in rheumatic diseases: a computational approach to identify miRNA association with cell types, cytokines, and disease mechanisms.Frontiers in immunology · 2023Review
- Exploration and validation of the influence of angiogenesis-related factors in aortic valve calcification.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmunity is involved in the valvular damage caused by rheumatic heart disease (RHD). Increased evidence has linked microRNAs (miRNAs/miRs) to autoimmune disease. Signal transducer and activator of transcription 3 (STAT3) and sphingosine‑1‑phosphate receptor 1 (S1PR1) and suppressor of cytokine signaling 1 (SOCS1) have been widely studied for their roles in autoimmunity and inflammation. Thus, the current study aims to investigate the role played by miR‑155‑5p in RHD‑induced valvular damage via the S1PR1, SOCS1/STAT3 and interleukin (IL)‑6/STAT3 signaling pathways. An RHD rat model was induced by inactivated Group A streptococci and complete Freund's adjuvant. A recombinant adeno‑associated virus (AAV‑miR155‑inhibitor) was used to inhibit the expression of miR‑155‑5p in the heart. Inflammation and fibrosis were assessed by hematoxylin and eosin staining and Sirius red staining. The expression of miR‑155‑5p in valvular tissues and serum exosomes was detected by reverse transcription‑quantitative PCR. S1PR1, SOCS1, STAT3, phosphorylated STAT3, IL‑6 and IL‑17 protein expression was detected by western blotting and immunohistochemistry. The relationships between miR‑155‑5p and S1PR1 and SOCS1 were detected by dual luciferase assays. Cytokine concentrations were measured by ELISA. The expression of miR‑155‑5p in valve tissues and serum exosomes was increased along with decreased S1PR1 and activated SOCS1/STAT3 signaling in the RHD model. The expression of IL‑6 and IL‑17 was increased in the valves and the serum. Dual luciferase assays showed that miR‑155‑5p directly targeted S1PR1 and SOCS1. Inhibition of valvular miR‑155‑5p through AAV pretreatment increased S1PR1 expression and inhibited activation of the SOCS1/STAT3 signal pathway as a result of attenuated valvular inflammation and fibrosis as well as a decrease in IL‑6 and IL‑17 in the valves and serum. These results suggest that inhibition of miR‑155‑5p can reduce RHD‑induced valvular damage via the S1PR1, SOCS1/STAT3 and IL‑6/STAT3 signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.